Real-world outcomes of patients with advanced intrahepatic cholangiocarcinoma treated with programmed cell death protein-1-targeted immunotherapy
Min Deng(First Affiliated Hospital of Bengbu Medical College), Rong Guo(Sun Yat-sen University), Qiaoxuan Wang(Institute of Polymers), Wei Wei(Zhujiang Hospital), Shaohua Li(Chinese Academy of Medical Sciences & Peking Union Medical College), Rongce Zhao(Sun Yat-sen University), Wen‐Ping Lin(Sun Yat-sen University), Jie Mei(Sun Yat-sen University), Jingwen Zou(Sun Yat-sen University)
Cited by 22
Related Papers
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion
|JAMA Oncology|2019|559
Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial
|Journal of Clinical Oncology|2020|217
Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy <i>versus</i> lenvatinib alone for advanced hepatocellular carcinoma
|Therapeutic Advances in Medical Oncology|2021|216
A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome
|European Journal of Endocrinology|2011|160